Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis.

Journal of viral hepatitis - 1 Nov 2024

Imsirovic Haris, Macphail Gisela, Conway Brian, Fraser Chris, Borgia Sergio, Smyth Daniel, Wong Alexander, Vachon Marie-Louise, Webster Duncan, Liu Hongqun, Feld Jordan, Lee Sam, Cooper Curtis

Abstract excerpt

The prevalence of mixed hepatitis C virus (HCV) genotype infection in a representative Canadian HCV cohort is reported and virological response with direct acting antiviral (DAA) treatment was evaluated. 3272 HCV-positive participants were enrolled, of which 2945 (90.0%) initiated DAA therapy. 0.8% were identified with mixed genotype infection. Overall sustained virological response (SVR) was 99.1% and did not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepacivirus
Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Canada

Share to Coinfection

Share to Hepatitis C, Chronic

Share to Prevalence

Share to Sustained Virologic Response

Share to Treatment Outcome

Source

Identifiers

PMID: 39135466
DOI: 10.1111/jvh.13995

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mixed-Genotype HCV Direct Acting Antiviral Outcomes: A CANUHC Analysis.PMID 39135466Read ↗

Pangenotypic direct-acting antiviral agents for mixed genotype hepatitis C infection: A real-world effectiveness analysis.Semantic proximity Read ↗

Prevalence of mixed genotype hepatitis C virus infections in the UK as determined by genotype-specific PCR and deep sequencing.Semantic proximity Read ↗

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?Semantic proximity Read ↗

Real-world effectiveness of glecaprevir/pibrentasvir and ledipasvir/sofosbuvir for mixed genotype hepatitis C infection: A multicenter pooled analysis in Taiwan.Semantic proximity Read ↗

Direct acting antivirals for the treatment of hepatitis C in ethnic minority populations.Semantic proximity Read ↗

Mixed genotype hepatitis C infections and implications for treatmentSemantic proximity Read ↗

The prevalence of mixed genotype infections in Polish patients with hepatitis C.Semantic proximity Read ↗

Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.Semantic proximity Read ↗

Hepatitis C virus deep sequencing for sub-genotype identification in mixed infections: A real-life experience.Semantic proximity Read ↗

Characteristics of patients with chronic infection due to hepatitis C virus of mixed subtype: prevalence, viral RNA concentrations, and response to interferon therapy.Semantic proximity Read ↗

Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin.Semantic proximity Read ↗

Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.